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Cancer patients can benefit from the Measles virus, since in the early 70s a relation between cancer remission 
and an infection with Measles was first mentioned (Bluming, Ziegler 1971). Further studies confirmed this 
oncolytic activity and therefore, the Measles virus became highly interesting for the application in cancer 
treatment. 
 
However, for the widespread application as a therapeutic agent several bottlenecks have to be overcome in 
context of quantity and quality. For one therapeutic dose of oncolytic Measles viruses (OMV) at least 1011 
infectious particles are needed (one vaccination contains ~103 TCID50) (Russell et al. 2014). 
Besides that, the impurities, such as host cell proteins (HCP) and host cell DNA (hcDNA), must be reduced to 
appropriate limits set by regulatory authorities. The full recovery of OMV infectivity must also addressed. This 
underlines the need of a tailor-made downstream processing. 
 
After we established a high titer production process, achieving OMV titers of 1011 TCID50 mL-1 (Grein et al. 
2017), we are now focused on the downstream processing of OMV. For this purpose we characterized the OMV 
regarding process parameters used in DSP, such as stability towards ionic strength, osmolality, agglomeration 
and shear stress. Based on this, a clarification step was conducted, followed by the further purification with 
tangential flow filtration (TFF). By using polyether sulfone flat sheet membranes in concentration mode, we were 
able to recover the infectious virus and lowered the impurities by ~70% for hcDNA and ~80% for protein content. 
In the next purification step, we applied a discontinuous diafiltration and could deplete the impurities by ~95% in 
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